

### Pharmaceutical traceability in Brazil

Ms. Bianca Zimon Giacomini Ribeiro, Deputy Chief Adviser for International Affairs, National Agency of Sanitary Surveillance (Anvisa), Brazil

18 October 2017






# Pharmaceutical traceability in Brazil The Brazilian Drug Control System SNCM





# Brazilian Drug Control System – SNCM Agenda




Legal basis
Objectives
Operational Dynamics
Computerized System






## Brazilian Drug Control System – SNCM Timeline






#### Brazilian Drug Control System – SNCM











# The National Drug Control System of Brazil






#### Brazilian Drug Control System – SNCM

Federal Law no. 13,410/2016







## **Identification and Data Capture**

#### **Secondary Packaging**

The RDC 157/2017 states that the GS1 DataMatrix bar code symbol should encode at least the following data that makes up the IUM (Unique Medicine Identification) in the following order:

I - GTIN - Global Trade Item Number

II - ANVISA Medicine Registry Number

III - Serial Number

IV - Expiration Date

V - Lot / Batch Number



#### **IUM - Unique Medicines Identification**


GTIN: (01)07898357410015

ANVISA's Number: (713)3210987654321

Serial: (21)1234567890123

Expire Date: (17)150206 Lot Number: (10)123ABC





## **Identification and Data Capture**

#### **Tertiary Packaging**

According to RDC157/2017 - Article 7.

Every transport package containing at least one medicinal product included in the SNCM experimental phase, from the registration holder's dispatch event instance, must have a <u>unique identifier</u> code that allows the relationship with the IUM of the medicinal products contained therein.






## **Data Storage**

Article 4-A. The Brazilian Drug Control System shall have a database centralized in a **Federal Government institution**, for storage and consultation on the movement of

drugs under its responsibility.






## Pilot project deadlines

I - up to one year: industry, importers, distribution and retail representatives chosen by the competent federal health surveillance institution may, on a experimental basis, receive and disseminate data on at least three drug batches;

II - up to eight months after phase I: results obtained during the experimental phase are object of assessment, correction, and validation report by ANVISA, through the Management Comittee;

III - up to three years: full implementation of the Brazilian Drug Control System.





## **Objective of the Pilot Project**

To validate the application of the Normative Instructions and its implementation guides:


Traceability process

System complexity

Technological integrations and their operation

Limitations





## **Operational Dynamics – NI 17/2017**

#### **Pilot Project Participants:**

Authorization holders (manufacturers or importers)


Distributors/ Wholesalers

Retailers


Hospitals


Other health establishments





## **Computerized System**





## **Computerized System**

End-to-end traceability

Performance

Information exchange

UIM

Allow use of different system models already addopted by companies

Wrong flows, losses, undue commercialization...





## Thank you!

Bianca Zimon
Advisor and Deputy Head
International Affairs Office

#### Contact

www.anvisa.gov.br www.twitter.com/anvisa\_oficial





